What happened in healthy volunteers?
A randomized, placebo-controlled trial studied finasteride in young men for 48 weeks. A subset provided repeated semen samples. Researchers found no significant effect on sperm concentration, total sperm count, movement or shape at the hair-loss dose studied.[1]
That is reassuring evidence for that population and time period. The study measured semen characteristics, however, rather than a person's eventual chance of becoming a parent.[1]
What happened in a fertility clinic?
A separate study reviewed 27 men taking finasteride who presented to a male infertility clinic. Sperm counts increased in many after the medication was discontinued. Hormone measurements, sperm movement and sperm shape did not show the same change.[2]
This was a selected group with fertility concerns, not a randomized sample of all finasteride users. It suggests that susceptibility can matter; it cannot tell every person taking the medicine how likely they are to experience a fertility problem.[2]
FDA prescribing information also includes postmarketing reports of male infertility or poor semen quality, with improvement or normalization reported after discontinuation. As with other voluntary reports, these cannot reliably establish frequency or causation on their own.[3]
What does that mean for planning a family?
The relevant details are whether pregnancy is a future goal or a current difficulty, any previous semen testing, and the medication history. Those details help frame a discussion about whether a fertility evaluation or a treatment change is appropriate. The clinic study gives particular reason to raise finasteride when low sperm counts are already part of the picture.[2]
Pregnancy exposure is a separate issue. FDA labeling says people who are pregnant or may become pregnant should not handle crushed or broken finasteride tablets because of potential risk to a male fetus. Intact tablets have a coating that prevents contact during normal handling.[3]
